Evaluation of Cetaphil Advanced Usage to Control Light to Moderate Atopic Dermatitis, in Attempt to Reduce the Necessity of Topic Corticoids Application

Phase IV - Evaluation of Cetaphil Advanced Usage to Control Light to Moderate Atopic Dermatitis, in Attempt to Reduce the Necessity of Topic Corticoids Application

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01063218

Enrollment

Registered

2010-02-05

Start date

2009-12-31

Completion date

2010-10-31

Last updated

2012-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dermatitis, Atopic

Keywords

Dermatitis, Atopic, Corticoids, topic, Corticosteroids

Brief summary

The main goal of this present study is evaluate the decreasing of necessity of topic corticoids usage to control outbreaks of light to moderate atopic dermatitis by using the correct emollients.

Interventions

OTHEREmollient - Cetaphil Advanced

Emollient - Cetaphil Advanced - to be applied twice a day for 20 weeks.

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

2 Years to 10 Years

Healthy volunteers

Yes

Inclusion criteria

* Male or Female patients * 2 to 10 years old. * with light to moderate with no signs of acute/ sub-acute eczema or in activity. * Subjects can not present inflammatory lesions, erythema, edema, eschar, excoriation and lichens. * Subjects can present light to moderate dryness.

Exclusion criteria

* Subjects presenting any serious systemic disease * Subjects with medical history regarding serious asthma * Subjects with known or suspected allergy to one of the investigational products * Subjects with acute atopic eczema or in activity, needing systemic antibiotics * Subjects with signs of active infections on skin * Subjects whose parents or legal guardian seem to have difficulty in understand the informed consent form (ICF) * Female subjects who are not in pre-menarche period. * Subjects who need topic corticoids or any other medication that can interfere on Atopic Dermatitis during the study. * Patient with a wash-out period for treatment less than: * injectable corticoids: 60 days * systemic corticoids: 15 days * topic corticoids: 8 days * topic immunomodulator: 8 days * antihistaminic : 48 hours

Design outcomes

Primary

Measure	Time frame
clinical evaluation	Baseline, Weeks 2, 4, 6, 8, 10, 12, 16, 20 and 24

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026